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INTRODUCTION
The primary neuropathological hall-
marks of Alzheimer’s disease (AD) com-
prise amyloid-β (Aβ) deposits and neu-
rofibrillary tangles composed of
abnormally phosphorylated tau protein
in the brain parenchyma (1). Deposition
of Aβ in brain is known to induce mi-
crogliosis (2) and attendant cytokine pro-
duction (3), events believed to be impor-
tant drivers of the pathogenic cascade
(4). There is a gathering interest in the
potential utility of cannabinoid interven-
tions for the prevention or treatment of
AD pathology, predicated on both the ro-
bust immune response evidenced in AD
pathology and the utility of cannabinoids
in dampening inflammatory pathways.
The endocannabinoid system com-
prises at least two biolipid signaling mol-
ecules produced on demand in a wide
spectrum of cell types and tissues, in-
cluding neurons and immune cells of the
central nervous system, that bind to at
least two cannabinoid receptors, CB1 and
CB2 (5). The CB2 receptor is expressed
primarily in immune-competent cells
and functions as a feedback inhibitor of
inflammatory cytokine production (6).
There is evidence that perturbations in
the endocannabinoid system may be ei-
ther a risk factor for or a biomarker of
AD. In a discovery-based gene expres-
sion experiment using microarray, CNR2,
the gene encoding the CB2 receptor, was
one of a select group of genes (from
Gene Chip of approximately 45,000
genes) identified as having increased ex-
pression in AD brain compared with age-
matched control brains (7). This study
was followed by an investigation of
mRNA expression in the blood of sub-
jects with AD in which expression of
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CNR2 was associated with AD and cor-
related with measures of cognitive im-
pairment (8). More recently, a study of
mRNA expression and epigenic regula-
tion of endocannabinoid system compo-
nents in the periphery of AD patients rel-
ative to controls revealed an increase in
the endocannabinoid-degrading enzyme
fatty acid amide hydrolase (FAAH), an
increase in FAAH protein levels, an in-
crease in FAAH activity and a reduction
in DNA methylation at the FAAH gene
promoter (9).
Neuropathological evidence supports
the involvement of the CB2 receptor in
plaque pathology of AD. Evidence of the
involvement of this receptor in disease
pathology emerged from a study in
which selective expression of the recep-
tor in neuritic plaque-associated mi-
croglia was demonstrated in regions im-
plicated early in disease progression
(hippocampus and entorhinal cortices) in
AD patients (10). Recently, increased re-
ceptor expression in frontal cortex (Brod-
mann area 10) of AD patients with more
advanced disease (Braak stage V/VI)
was found to correlate with amyloid
(Aβ) levels and plaque density score (11).
The localization of CB2 receptor–positive
microglia in regions of human AD
pathology contextualized within the role
of the immune cell–expressed CB2 recep-
tor as a feedback inhibitor of immune re-
sponsiveness suggests a participatory
role for this receptor system in the in-
flammatory pathology of AD and the po-
tential for a novel target for intervention.
Promising in vitro studies investigating
cellular and pathological models have
gradually given way to direct in vivo ex-
periments focused on cannabinoid thera-
peutics for the interruption of the Aβ
deposition cascade of AD.
CB2 receptor stimulation in AD as a vi-
able strategy for preventing Aβ-induced
microglial activation and ameliorating
cognitive impairment was first demon-
strated in a nontransgenic animal model
of AD (12). In this experiment, intracere-
broventricular injections of Aβ or control
peptide were administered to mice with
and without a cannabinoid. As expected,
activated microglia were observed in the
cortex of Aβ-treated mice. It was demon-
strated that cannabinoid treatment with
Aβ prevented microglial activation and
that although Aβ-treated mice mani-
fested very typical AD model impair-
ments of spatial navigation, the cannabi-
noid prevented this Aβ-induced
cognitive impairment. Recently, investi-
gators exposed 11-month-old transgene
amyloid precusor protein (TgAPP) 2576
mice to prolonged treatment with a syn-
thetic CB2 receptor agonist, JWH-133
(13). When compared with vehicle-
treated mice, JWH-133 treatment reduced
microgliosis, decreased soluble Aβ40 and
Aβ42 and enhanced glucose metabolism
in the hippocampus and cortical regions,
suggesting that targeting the microglial
CB2 receptor interrupts critical events in
the amyloid cascade via a direct impact
on microglial activation. A subsequent
investigation with the same compound
in APP/presenilin 1 (PS1) mice revealed
that treatment induced cognitive im-
provement, as well as reduced expres-
sion of the proinflammatory cytokines
interleukin (IL)-1β, IL-6, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ
(14). Recently, a novel CB2 agonist
(MDA7) was shown to promote Aβ clear-
ance, decrease IL-1β and improve mem-
ory in rats with cognitive impairment in-
duced by bilateral microinjections of Aβ
into the hippocampus (15).
Beyond the impact on Aβ, cannabi-
noid interventions may influence tau
processing, mediated by inflammatory
pathways. Emerging evidence suggests
that neuroinflammation may be a criti-
cal event in tangle production (16).
From the perspective of cellular pathol-
ogy, activated microglia have long been
known to be spatially associated with
tangle pathology (17). In a recent study,
it was demonstrated that glial re-
sponses correlate positively with tangle
burden and are more likely to be found
in the vicinity of tangles (18). Relation-
ships between inflammation and alter-
ations in the processing of tau proteins
have been suggested. Activated mi-
croglia cultured with cortical neurons
induce tau phosphorylation, mediated
by p38 mitogen–activated protein ki-
nase pathways (19). In a mouse model
expressing P301S-mutated tau, mi-
croglial activation preceded tangle for-
mation, suggesting that inflammation
may drive intraneuronal changes in tau
processing (20). Lipopolysaccharide in-
jection into the brains of mice express-
ing human mutant tau induces mi-
croglial activation and phosphorylation
of tau (21,22). These data suggest that
targeted interruption of inflammatory
pathways in the absence of amyloid
with cannabinoid therapies may influ-
ence tau processing and potentially tan-
gle production.
To investigate in what way the CB2 re-
ceptor is involved in AD pathogenesis,
we designed an experiment to determine
whether knocking out the CB2 receptor
influences Aβ production, plaque deposi-
tion or related pathologies in APP trans-
genic mice. To this end, we established a
colony of mice with a deleted CB2 recep-
tor gene (CNR2) on a transgenic human
mutant APP background for pathological
comparison with CB2 receptor sufficient
transgenic mice. In addition to Aβ-
 dependent endpoints, the effect of CB2
receptor deletion on total soluble mouse
tau production and hyperphosphory-
lated tau (at a conformational changing
epitope [Ser396/404] known to be a prin-
cipal component of neurofibrillary tan-
gles) were assayed by using a recently
developed high-sensitivity assay created
in our laboratory (23).
MATERIALS AND METHODS
Animals
CB2 receptor knockout mice
(CNR2–/–). The Cnr2tm1Dgen/J knockout
mouse was developed by homologous
recombination resulting in a 334–base
pair deletion in the coding exon of the
CNR2 gene, with a neomycin gene inser-
tion germinated in a C57/BL6 mouse.
Macrophages from homozygous mutant
mice lacking the CB2 receptor are resist-
ant to the inhibitory effects of δ-9
tetrahydrocannabinol (24). Beyond alope-
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cia, there are no other reported pheno-
typic aberrations in these mice (25). Con-
sistent with the effects of the CB2 system
on immune modulation, CNR2–/– mice
have been reported to exhibit more se-
vere experimental autoimmune en-
cephalitis than wild-type mice as well as
enhanced allergic responses (26,27). It
has been previously demonstrated that
CNR2–/– mice expressing the human mu-
tant Huntington exon 1 (R6/2 mice) have
increased microglial activation (detected
via immunostaining with ionized
 calcium-binding adapter molecule 1 
[Iba-1] antibody) and exacerbated dis-
ease progression when compared with
CNR2+/+ R6/2 mice (28).
Transgenic amyloid mice (J20). The
J20 mouse expresses a mutant form of
the amyloid precursor protein bearing
the K670N/M671L and V717F mutations
inserted via the human platelet–derived
growth factor β polypeptide promoter
into C57/BL6 × DBA/2 F2 one-cell em-
bryos; hemizygous mice express trans-
gene product in cerebral neurons, espe-
cially the neocortex and hippocampus
(29). At 5 months of age, diffuse Aβ dep-
osition in the dentate gyrus and neocor-
tex is first evident. Plaques are evident in
50% of J20 mice by 7 months and nearly
100% of mice by 8 months and demon-
strate a significant reactive microgliosis
(29,30).
J20 CNR2–/– mice. The goal of the pres-
ent study was to establish a colony of
transgenic amyloid mice lacking the CB2
receptor for comparison with transgenic
amyloid mice with an intact CB2 receptor
system (J20 CNR2–/– and J20 CNR2+/+).
To create a strain of J20 CNR2–/– mice, J20
mice were backcrossed with J20 CNR2–/–
mice over two generations, first produc-
ing a generation of J20 CNR2+/– mice,
then J20 CNR2–/– mice. Mice were gender
matched and raised to 1 year before
being euthanized. All animal experiments
were performed according to procedures
approved by the Feinstein Institute for
Medical Research Institutional Animal
Care and Use Committee. CNR2 knock-
out (strain name B6.129P2-Cnr2tm1Dgen/J)
mice and TgAPP [strain name B6.Cg-
Tg(PDGFB-APPSwInd)20Lms/2Mmjax,
also known as “J20”] transgenic mice,
both on a C57BL/6 background, were ob-
tained from The Jackson Laboratory (Bar
Harbor, ME, USA).
Genotyping
Genotyping was performed at
Transnetyx (Cordova, TN, USA) from
tail samples, by using a quantitative
polymerase chain reaction (qPCR)-based
system to detect the presence or absence
of a target sequence within each sample.
The APP probe was targeted to the
human cDNA exon–exon junction se-
quence and detects the presence of that
transgene within a sample. The CNR2
probe was targeted to a sequence in the
disrupted CNR2 gene and detects the
presence of a neomycin cassette within
each sample. J20 CNR2+/+, J20 CNR2–/–,
CNR2–/– and wild-type (WT) mice were
group-housed (three to five animals per
cage) with a 12:12-h light/dark cycle
and with ad libitum access to water and
food. At 52 wks of age (12 months),
mice were killed. Brains were hemidis-
sected, and one hemibrain was fixed
with 4% paraformaldehyde in 0.1 molar
phosphate-buffered saline (pH 7.6),
whereas the other hemibrain was se-
quentially extracted, as described in
previously published protocols (31).
Paraformaldehyde-fixed brain hemi-
spheres were dehydrated in ethanol,
paraffin- embedded and cut with a mi-
crotome into 5-μm sagittal sections.
Enzyme-Linked Immunosorbent
Assay: Aβ, DA31 and PHF1 Levels
Hemisectioned brains were homoge-
nized and sonicated in Tris-buffered
saline containing 2% sodium dodecyl sul-
fate (SDS) and 1× cOmplete protease in-
hibitor mixture (Roche Applied Science,
Indianapolis, IN, USA) and centrifuged at
100,000g for 1 h at 4°C. The supernatant
was then removed, and the resulting pel-
let was extracted with 70% formic acid in
water. The 2% SDS extracts were diluted
1:40. Formic acid extracts were neutral-
ized initially by a 1:20 dilution into
1 mmol/L Tris phosphate buffer (pH 11)
and then diluted as necessary to normal-
ize protein concentration. Brain Aβ40 and
Aβ42 were quantified using an  enzyme-
linked immunosorbent assay (ELISA) kit
following the manufacturer’s instructions
[Human β Amyloid (1-40) ELISA Kit (cat.
no. 292-62301) and Human β Amyloid
(1-42) ELISA Kit (cat. no. 298-62401);
Wako, Richmond, VA, USA]. ELISA
plates were read on a Tecan GENios Pro
reader (Tecan Group Ltd., Männedorf,
Switzerland) at 450 nmol/L. Low-tau
sandwich ELISA was performed to detect
total tau (DA31) and pSer396/404 (PHF1)
levels. Briefly, 96-well plates were coated
with DA31 (or PHF1 at a final concentra-
tion of 6 μg/mL for 48 h at 4°C). After
washing and blocking, 50 μL of each sam-
ple was added in duplicate, using the
proper dilution in 20% SuperBlock
(Thermo Scientific, part of Thermo Fisher
Scientific Inc., Waltham, MA, USA):
1:10,000 for the DA31 ELISA  (antibody-
coated plates provided by P Davies), and
1:5,000 for the PHF1 ELISA (antibody-
coated plates provided by P Davies), re-
spectively. At the same time, 50 μL DA9-
HRP detection antibody was added to the
wells and tapped to combine. Plates were
incubated overnight by shaking at 4°C.
After washing, the 1-Step ULTRA TMB-
ELISA substrate (Thermo Scientific) was
added for 30 min at room temperature
and then blocked with 2 mol/L sulfuric
acid. Plates were read with an Infinite
m200 plate reader (Tecan) at 450 nmol/L.
The measured values were normalized
according to the protein concentration.
Immunocytochemistry (ICC)
All ICC analysis took place in tripli-
cate; three paraffin- embedded sections
were selected from each mouse for each
antibody representing equally staggered
sagittal cutting intervals. For Αβ staining,
sections were processed according to pre-
viously published protocols (32). Briefly,
sections were pretreated with 70% formic
acid for 15 min and immersed in 1%
H2O2 for 30 min. Sections were then incu-
bated with 5% milk in Tris-buffered
saline for 1 h and with 6E10 primary anti-
body (1:1,000 dilution; Covance Inc.,
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Princeton, NJ, USA) overnight at 4°C. In-
cubation with biotin-labeled goat anti-
mouse IgG1 secondary antibodies (1:1,000
dilution; SouthernBiotech, Birmingham,
AL, USA) was performed before incuba-
tion with streptavidin-horseradish perox-
idase (SouthernBiotech) and diaminoben-
zidine tetrahydrochloride. For microglial
staining, sections were first pretreated
with Dako Target Retrieval Solution at
95°C for 30 min and then processed with
a similar protocol by using the Iba-1 pri-
mary antibody (1:1,000 dilution; Wako),
followed by biotin-labeled goat anti-rab-
bit secondary antibody (1:1,000 dilution;
SouthernBiotech). Sections were observed
with a light microscope, and pictures
were generated by using an Olympus 5
megapixel camera (Olympus Corporation
of the Americas, Center Valley, PA, USA).
Image analysis for quantification of ICC
(staining density) used grayscale thresh-
olding and pixel estimation/ conversion
to percent area stained with ImageJ soft-
ware (NIH, Bethesda, MD, USA; http://
imagej.nih.gov/ij), following previously
described techniques (33). Percent area
stained was then averaged for sections an-
alyzed in triplicate from each mouse and
compared by group (J20 CNR2+/+ versus
J20 CNR2–/–). For cellular quantification of
plaque-associated microglia, with Iba-1
staining, two representative plaques were
selected from each mouse; plaques were
identified by the characteristic clustering
of reactive microglia in a circular profile,
defining the circumference of the plaque.
Iba-1-positive microglia were counted
along the circumference of the plaques
and then compared by group.
Statistical Analysis
Between-group statistical analyses
were performed with unpaired Student 
t tests for differences between two-group
means, and analysis of variance
(ANOVA) where appropriate, by using
GraphPad Prism Software (GraphPad
Software Inc., La Jolla, CA, USA).
RESULTS
To evaluate the impact of the CB2 re-
ceptor on amyloid pathology, microglio-
sis and tau processing, a colony of J20
CNR2+/+ and J20 CNR2–/– mice was es-
tablished. A total of 17 J20 CNR2+/+ mice
(12 female, 5 male) and 16 J20 CNR2–/–
mice (11 female, 5 male) were euthanize
after 1 year, and brain sections were
taken for immunohistochemistry and
biochemistry. The duration of the study
was set at 1 year, to allow ample time for
plaque production and microgliosis,
while avoiding loss of mice from age-re-
lated mortality issues in the transgenic
model. Because there have been reports
of amyloid production being influenced
by gender in transgenic models (34), the
groups were matched for gender (one fe-
male J20 CNR2–/– mouse died before the
1-year time point).
Our approach involved a combination
of biochemistry interrogating levels of sol-
uble Aβ40 and Aβ42, and immunohisto-
chemistry for quantification of plaque
pathology. Previous experiments have
demonstrated that CB2 receptor stimula-
tion in cell culture promotes successful
phagocytosis of the Aβ42 peptide, the
chief component of plaque pathology (35).
This result would suggest that the ab-
sence of the receptor system would drive
increases in Aβ42 and plaque pathology.
When AD brains are compared with con-
trols, both levels of soluble and insoluble
(aggregated, plaque associated) Aβ in-
crease, but there is a shift from soluble
forms to insoluble forms such that, in AD,
insoluble Aβ dominates the total fraction
of amyloid in the brain, whereas in
healthy controls, soluble forms predomi-
nate (36). CB2 receptor–mediated reduc-
tion in Aβ levels in J20 CNR2+/+ mice, me-
diated by phagocytosis of organized
plaque, was predicted to be primarily evi-
dent in plaque size, with a secondary ef-
fect on soluble Aβ species as reservoirs of
Aβ drop.
The J20 CNR2+/+ and J20 CNR2–/– mice
differed primarily on immunohistochemi-
cal measurements of plaque pathology,
with a smaller impact on soluble Aβ
species. Plaque staining density assessed
by ICC differed between groups, reflecting
increased deposition in the hippocampus
(Figure 1A–C), anterior cortex (Figure 1D)
and posterior cortex (Figure 1E) of J20
CNR2–/– mice. This result is consistent
with the expectation that any increase in
pathology in J20 CNR2–/– mice would be
driven by impaired microglial phagocytic
reduction of plaques. The biochemical
analysis, using ELISA to evaluate soluble
forms, revealed that while soluble Aβ42
was significantly increased in CNR2-
 deficient mice (Figure 2B), soluble Aβ40
did not differ significantly between groups
(Figure 2A). Because Aβ42– rather than the
more common Aβ40– is known to be the
more fibrillogenic isoform, the reported el-
evation is consistent with the evident in-
crease in plaque pathology (37).
An increased microglial response was
anticipated in J20 CNR2–/– mice. It has
been demonstrated that the CB2 receptor
stimulation has an immunosuppressive
effect (38,39), blocking the production of
proinflammatory cytokines (40) and that
simulation of the CB2 receptor inhibits
microglial activation. Direct CB2 receptor
stimulation has been shown to prevent
Aβ-induced microglial activation in an
animal model of AD and improves cogni-
tive outcomes, highlighting the negative
consequence of microglial response in
amyloid models (12). Mice lacking the
CB2 receptor, deficient in the feedback in-
hibition of microglial activation that the
receptor provides, would be expected
under conditions of Aβ plaque deposition
to evidence a higher density of  microglial
representation. To quantify microglial ac-
tivation, our approach used immunohis-
tochemical analysis of tissue with the mi-
croglial marker Iba-1. Iba-1 is a protein
that is specifically expressed by
macrophages and microglia and is upreg-
ulated under conditions of activation
(41). Microgliosis, quantified with im-
munohistochemistry (Iba-1) staining den-
sity did not, contrary to expectation, dif-
fer significantly between J20 CNR2–/– and
J20 CNR2+/+ mice (Figure 3A). However,
plaque-associated microglia (a more local
barometer of Aβ plaque–driven inflam-
mation) were significantly more promi-
nent in J20 CNR2–/– mice (Figure 3B).
To explore the relationship between
microglial-driven alterations in amyloid
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deposition and tau pathology in the J20
mouse, total soluble mouse tau (assayed
with DA31) ELISA and Ser396/404
 phospho-tau (assayed with PHF1 ELISA)
were compared between the J20 CNR2–/–
mouse and the J20 CNR2+/+ mouse. Total
tau was significantly reduced in J20
CNR2–/– mice (Figure 4A). A recent re-
view of experimental manipulations of
microglia in amyloid mouse models has
reported that in published studies evalu-
ating both amyloid and tau outcomes,
changing the state of microglial activa-
tion has inverse effects on amyloid and
tau pathology; experimental interven-
tions that drive amyloid down as a func-
tion of microglial activity and phagocy-
tosis (for instance, deletion of the
fractalkine receptor, or the administra-
tion of LPS) increases tau pathology (42).
The pathways connecting proinflamma-
tory reduction of amyloid and tau exac-
erbation are not as yet clear. However,
because experimentally enhancing micro-
gial phagocytosis of amyloid may drive
tau pathology, perhaps via factors re-
leased by the microglia themselves in re-
sponse to these manipulations and not as
the result of amyloid (42), it may be that
the deletion of the microglial CB2 recep-
tor in the context of amyloid-driven mi-
croglial activation reduces tau.
Like other APP transgenic mouse mod-
els, J20 mice do not develop neurofibril-
lary tangle pathology. A previous study
reported, however, that in the cortex and
hippocampus of aged TgCRND8 amyloid
mice, tau is hyperphosphorylated at the
Ser396/404 epitope known to be a princi-
pal component of neurofibrillary tangles
(43). To date, no studies have used ELISA
to quantify soluble total tau and
Ser396/404 phospho-tau in J20 mice. Our
approach used ELISA because it has an
advantage over Western blot and im-
munohistochemical approaches in its
ability to give an exact quantification of
protein concentration. Because there is no
aggregated tau-forming neurofibrillary
tangle pathology in transgenic amyloid
mice such as the J20, most of the tau
would be anticipated to be present in sol-
uble form, making the soluble tau ELISA
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Figure 2. (A) Quantification of soluble Aβ40 in hemisectioned brains of CB2-deficient ver-
sus CB2-sufficient mice. Data are means. (B) Quantification of soluble Aβ42 in hemisec-
tioned brains of CB2-deficient versus CB2-sufficient mice. Data are means and 95% confi-
dence intervals). *p < 0.05.
Figure 1. (A, B) Representative sections at 4× magnification reflecting ICC staining sample
means in mouse hippocampus (A: J20 CNR2+/+; B: J20 CNR2–/–). (C) Quantification of
human amyloid ICC staining in mouse hippocampus using 6E10 monoclonal antibodies.
Data are means and 95% confidence intervals. (D) Quantification of human amyloid ICC
staining in anterior mouse cortex using 6E10 monoclonal antibodies. Data are means and
95% confidence intervals. (E) Quantification of human amyloid ICC staining in posterior
J20 mouse cortex with 6E10 monoclonal antibody. Data are means and 95% confidence
intervals. *p < 0.05.
a sensitive approach. A previous study
has demonstrated an inhibitory effect of
CB2 receptor stimulation with JWH-133
on several tau kinases, including GSK3β,
in an amyloid mouse model of AD, and a
reduction in one phospho-tau epitope not
investigated in the current study (14). For
this reaseon, we anticipated elevations of
soluble Ser396/404 phospho-tau in J20
CNR2–/– mice. However, levels of
Ser396/404 phospho-tau were reduced in
the J20 mouse relative to controls and in
J20 CNR2–/– mice (Figure 4B). Of note,
the JWH-133 stimulation reported (14)
did not result in any modification in Aβ
plaque deposition, a condition different
from the current report. As noted above,
microglial conditions that drive changes
in amyloid may have a different impact
on tau processing than conditions that do
not. Because total tau was reduced in the
J20 CNR2–/– mouse (as discussed above),
and because DA31 includes all tau pro-
tein (even phosphorylated tau), we evalu-
ated the ratio of Ser396/404 to total tau to
evaluate the relative proportion of this
pathogenic species represented in total
tau. The ratio of Ser396/404 to total tau
was decreased only in J20 CNR2+/+ mice
relative to J20 CNR2–/– mice and controls
(Figure 4C). This result suggests that in
the J20 mice, there may be a shift in the
relative activity of tau kinases, with a re-
duction in the kinases responsible for
phosphorylating Ser396/404. The J20
CNR2–/– mouse, however, had an in-
crease in the ratio of Ser396/404 phosho-
tau to total tau when compared with the
J20 CNR2+/+ mouse. It may be that in the
J20 CNR2–/– mouse, the mechanism re-
sponsible for the relative reduction of
total tau precedes  kinase-driven phos-
phorylation, such that there is a relative
elevation of the Ser396/404 ratio in the
J20 CNR2–/– mouse relative to the J20
CNR2+/+ mouse (Figure 4C) that does not
reflect any difference in the activity of the
responsible tau kinase. It is also possible
that as CB2 receptor stimulation has been
shown to reduce the activity of tau ki-
nases and lower tau phosphorylation
(14), there is a relative increase in kinase
activity in CB2-deficient mice compensat-
ing for the reduction in the J20 mouse. 
DISCUSSION
The flourish of recent reports of the role
of the CB2 receptor in AD (11) and of the
CB2 receptor manipulation in mouse
models of AD (13–15) suggest that the
field of AD therapeutics is moving toward
experimental cannabinoid interventions
in humans, perhaps targeting the CB2 re-
ceptor. Of note, each of these studies fo-
cused on amyloid models of disease, and
only one study included tau outcomes
(14). Although the results of the tau-out-
come experiment suggest a salutary effect
on phosphorylated tau via CB2 receptor
stimulation, the study only looked at one
phosphorylation epitope (Thr181), and
only quantified via immunofluorescent
staining in the regions of plaques, and not
throughout the cortex. Given the potential
exacerbation of tau pathology achieved
via microglial-targeted reduction of amy-
loid, including tau outcomes in amyloid
models is important in evaluating the
risks and benefits of moving forward with
human trials (42).
Although previous studies have evalu-
ated changes in plaque deposition in re-
sponse to manipulations of the CB2 re-
ceptor, no previous studies have
evaluated the constitutive role of the CB2
receptor in reducing plaque deposition;
the production of a transgenic APP/CB2
knockout mouse afforded the opportu-
nity to evaluate the role of the microglial
CB2 receptor without pharmacological
intervention. J20 CNR2–/– mice had in-
creased plaque pathology in the hip-
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Figure 4. (A) Quantification of soluble DA31 in hemisectioned brains of mice. Data are
means and 95% confidence intervals. (B) Quantification of PHF1 in hemisectioned brains
of mice. Data are means and 95% confidence intervals. (C) PHF1/DA31 ratio. *p < 0.05.
Figure 3. (A) Quantification of ICC Iba-1 staining in mouse hippocampus using Iba-1 mon-
oclonal antibody. Data are means (no significant differences observed). (B) Quantification
of plaque-associated microglia with Iba-1 in mouse hippocampus. Data are means and
95% confidence intervals. (C) Representative sections at 40× magnification reflecting av-
erage plaque-associated microgliosis in mouse hippocampus. *p < 0.05.
pocampus, anterior cortex and posterior
cortex. This result is consistent with one
previous report (13) demonstrating the
efficacy of oral canabinoid administra-
tion in reducing Aβ, although a subse-
quent study looking at a different com-
pound found an improvement in
cognition putatively mediated by mi-
croglial manipulation without alterations
in levels of Aβ (14). While there was an
increase in soluble, nonaggregated Aβ42
in the J20 CNR2–/– mouse, and while the
mean levels of soluble Aβ40 were higher
in the J20 CNR2–/–, elevations in Aβ40
did not reach statistical significance. A
larger sample size may have yielded dif-
ferent results.
It was anticipated that CB2 receptor
deletion in the J20 mouse would result in
an upregulation of microglial activation
and that the CB2 receptor would enhance
microglial chemotaxis, driven primarily
by Aβ, via an endocannabinoid concen-
tration gradient to the regions of plaque,
such that, in knockout mice, there would
be less plaque-associated microglia (44).
Although we did find an increase in
plaque burden in CB2  receptor–deficient
mice, we had anticipated a broader mi-
croglial response reflected in increased
Iba-1 staining. This result was suggested
by a previous experiment in which CB2
receptor stimulation reduced Iba-1-
 positive microglia in TgAPP mice by
>50% (13). It may be that downregula-
tion of microglial response occurs only
locally to plaques, in regions of increased
endocannabinoid production; this is con-
sistent with our finding of decreased
plaque-associated microglia in CB2
receptor–sufficient mice. Although it is
conceivable that microglial phagocytosis
of plaque is enhanced by the activation of
the CB2 receptor, it is also possible that
this is observed only in the context of ex-
ogenous, rather than endogenous, stimu-
lation. The reported  results challenge the
notion that the CB2 receptor, in the ab-
sence of exogenous stimulation, enhances
chemotaxis of microglia to regions of
plaque deposition, since receptor-
 deficient mice had more plaque-associated
microglia. The enhanced presence of
plaque-associated microglia in receptor-
deficient mice together with enhanced
plaque deposition also challenges the 
notion that increased recruitment of 
microglia to regions of plaque necessarily
results in an augmentation of plaque clear-
ance and suggests that microglial phago-
cytosis of Aβ in CB2 receptor–deficient
mice may be relatively impaired. The
specific advantage of CB2 receptor stimu-
lation in successful phagocytosis of Aβ42
fragments has been previously demon-
strated in vitro and, in the context of these
results, underscores the need for further
in vitro studies evaluating the potential
negative impact of microglial CB2 recep-
tor deficiency on phagocytosis (45).
CONCLUSION
The reported diminution of total tau in
the J20 CNR2–/– mouse in the context of
elevations in Aβ is consistent with previ-
ous studies evaluating the impact of
proinflammatory manipulations of mi-
croglia in amyloid mouse models, in
which Aβ reductions were associated
with increases in tau (42). In the absence
of microglial manipulation, and in stud-
ies of tau mutants, levels of Aβ and tau
have been more correlative. For instance,
in one study of the TgCRND8 APP
mouse, aged mice were found to have in-
creased PHF1 immunoreactivity by West-
ern blot relative to wild-type mice (43).
Total tau proteins did not differ between
TgCRND8 mice and nontransgenic age-
matched controls. In studies of amyloid
immune therapy in 3xTg-AD mice (that
incorporate both amyloid and tau muta-
tions), reductions in amyloid were also
coupled with proteasome-dependent re-
ductions in tau, including total soluble
tau measured with ELISA (46,47). Al-
though the relationship between Aβ dep-
osition and tau production is complex,
and experiments using different models
may show relationships between these
pathogenic proteins in different direc-
tions, it is clear that incorporating both
Aβ and tau outcomes is critical to antici-
pate what may happen in experimental
trials of human disease. The current re-
port suggests that cannabinoid CB2-
 targeted interventions that reduce Aβ
deposition may have altered tau proteins
in undesirable directions.
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